Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Chief Accounting Officer | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,500 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 6,500 · Balance 6,500 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01 | Direct | 19,000 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 19,000 · Balance 19,000 F2: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030.
F2: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 16:18 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001453687-26-000034 · wk-form4_1767734330.xml · derivative · entry 2 Seymour June Ann · CIK 0002093716 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:18 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-26-000034 · wk-form4_1767734330.xml · nonDerivative · entry 1 Seymour June Ann · CIK 0002093716 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 16:05 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001453687-25-000112 · wk-form4_1761681948.xml · derivative · entry 1 Seymour June Ann · CIK 0002093716 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-10-27 F1 · derivative.exercise_date: This option vests as to 25% on October 27, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on October 27, 2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.